主页 文献库文献详情
PMID: 22571696 已发表 · ppublish 英语

5q- syndrome.

Current pharmaceutical design ·第 18 卷 ·第 22 期 ·2012-10-30

Boultwood Jacqueline, Pellagatti Andrea, Wainscoat James S

摘要

In recent years we have gained great insight into the molecular pathogenesis of the 5q- syndrome, the most distinct of all the myelodysplastic syndromes. It is now recognized that p53 activation, caused by haploinsufficiency for the ribosomal gene RPS14 (mapping to the commonly deleted region), is the probable cause of the erythroid defect in the 5q- syndrome. A mouse model of the human 5q- syndrome has been generated by large-scale deletion of the Cd74-Nid67 interval (containing Rps14) and the crossing of these '5q- mice' with p53-deficient mice ameliorated the erythroid progenitor defect. Recent evidence suggests that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome. Emerging data shows that p53 mutation may play a role in disease progression.

文献信息
期刊
Current pharmaceutical design
期刊简称
Curr Pharm Des
发表日期
2012-10-30
收录日期
2012-06-27
更新日期
2015-11-19
语言
英语
国家/地区
Netherlands
NLM ID
9602487
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]